Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
20 hedge funds and large institutions have $40M invested in Soleno Therapeutics in 2019 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 4 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
33% more capital invested
Capital invested by funds: $30.2M → $40M (+$9.87M)
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
0.03% less ownership
Funds ownership: 46.09% → 46.06% (-0.03%)
9% less funds holding
Funds holding: 22 → 20 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$183K |
| 2 |
BlackRock
New York
|
+$76.8K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$69.4K |
| 4 |
TMC
Trellus Management Company
Delray Beach,
Florida
|
+$63K |
| 5 |
Bank of New York Mellon
New York
|
+$40.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$209K |
| 2 |
VF
Virtu Financial
New York
|
-$72K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$65.6K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$37K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$31K |
SLNO Hedge Fund Activity: Q2 2019 in Review
20 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q2 2019, worth a combined $40M — up 33% from $30.2M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of SLNO and 2 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 6 added.
The largest buyer was Renaissance Technologies, adding an estimated $183K. The largest seller was Vivo Capital, cutting an estimated $209K.
- 20 institutional investors held Soleno Therapeutics (SLNO) as of Q2 2019, down from 22 in Q1 2019.
- Funds reported $40M of Soleno Therapeutics stock for Q2 2019, up 33% quarter-over-quarter.
- 2 funds opened new Soleno Therapeutics positions in Q2 2019 and 4 closed out, a net change of -2 holders.
- The largest Soleno Therapeutics buyer in Q2 2019 was Renaissance Technologies, an estimated $183K added.
- The largest Soleno Therapeutics seller in Q2 2019 was Vivo Capital, an estimated $209K sold.
Based on aggregated 13F filings for Q2 2019.